Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Keros Therapeutics, Inc.
| Metric | Keros Therapeutics, Inc. KROSHealthcare |
|---|---|
| Quality Score | 93 / 100 |
| Revenue (latest) | $244M |
| Net income (latest) | $87M |
| Operating margin | 27.7% |
| Net margin | 35.7% |
| Return on equity | 28.7% |
| Return on assets | 25.7% |
| Return on capital (ROCE) | 21.3% |
| Debt / equity | 0.12× |
| Revenue growth (YoY) | 6775.0% |
| Altman Z″ (distress) | 11.55 |
| Accruals / assets | −6.1% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.